PMCB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PMCB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PharmaCyte Biotech's Book Value per Share for the quarter that ended in Jan. 2024 was $3.68.
During the past 12 months, PharmaCyte Biotech's average Book Value per Share Growth Rate was -13.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was -2.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was -12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of PharmaCyte Biotech was 28.40% per year. The lowest was -405.80% per year. And the median was -19.45% per year.
For the Biotechnology subindustry, PharmaCyte Biotech's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
PharmaCyte Biotech (NAS:PMCB) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Thank you for viewing the detailed overview of PharmaCyte Biotech's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Wayne Remell Walker | director | 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103 |
Robert Weinstein | director | 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169 |
Jack E Stover | director | C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902 |
Daniel Stuart Farb | director | 100 ESSEX RD., CHESTNUT HILL MA 02467 |
Jonathan Schechter | director | C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165 |
Daniel Allen | director | 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Matthias Loehr | director | 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169 |
Yuen Thomas C K | director | |
Carlos Trujillo | director, officer: CFO | 8105 IRVINE CENTER DR. #820, IRVINE CA 92618 |
Kenneth L. Waggoner | director, officer: Chairman, CEO, Pres and GC | 8105 IRVINE CENTER DR. #820, IRVINE CA 92618 |
Gerald W Crabtree | director, officer: Chief Science Officer | 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904 |
Thomas Liquard | director | C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653 |
Raymond Cf Tong | director | C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099 |
Michael M Abecassis | director | C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099 |
From GuruFocus
By PRNewswire PRNewswire • 06-19-2022
By PRNewswire PRNewswire • 06-10-2022
By PRNewswire PRNewswire • 07-13-2022
By Business Wire Business Wire • 07-19-2022
By PRNewswire PRNewswire • 07-15-2022
By Business Wire Business Wire • 06-13-2022
By Business Wire • 10-31-2023
By PRNewswire PRNewswire • 07-28-2022
By Business Wire Business Wire • 06-15-2022
By Business Wire Business Wire • 07-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.